SCOPUS 정보 검색 플랫폼

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6309-6310

Estrogen receptor-negative breast cancer: New insights into subclassification and targeting

(2) Zhao, Jean J a,b Silver, Daniel P a,b

a DANA FARBER CANCER INSTITUTE (United States)

b HARVARD MEDICAL SCHOOL (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; IMATINIB; LAPATINIB; TRASTUZUMAB;

BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; HUMAN; LUNG CANCER; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHOTRANSFERASES; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 70350244859 PISSN: 10780432 EISSN: None Source Type: Journal
DOI: 10.1158/1078-0432.CCR-09-2010 Document Type: Note

Times cited : (5)

References (11)

1
- 70350235064
- Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer
- Speers C, Tsimelzon A, Sexton K. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 2009;15;6327-6340
- (2009) Clin Cancer Res , vol.15 , pp. 6327-6340
- Speers, C.¹ Tsimelzon, A.² Sexton, K.³

2
- 37049183697
- Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182
- (1987) Science , vol.235 , pp. 177-182
- Slamon, D.J.¹ Clark, G.M.² Wong, S.G.³ Levin, W.J.⁴ Ullrich, A.⁵ McGuire, W.L.⁶

3
- 0034680102
- Molecular portraits of human breast tumours
- Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752
- (2000) Nature , vol.406 , pp. 747-752
- Perou, C.M.¹ Sorlie, T.² Eisen, M.B.³

4
- 13844273459
- Trastuzumab in breast cancer
- Huntingt discussion 31-2, 37-38
- Emens LA, Davidson NE. Trastuzumab in breast cancer. Oncology (Huntingt) 2004;18:1117-28; discussion 31-2, 37-38
- (2004) Oncology , vol.18 , pp. 1117-1128
- Emens, L.A.¹ Davidson, N.E.²

5
- 26844503270
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
- DOI 10.1056/NEJMoa052306
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672 (Pubitemid 41464705)
- (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1659-1672
- Piccart-Gebhart, M.J.¹ Procter, M.² Leyland-Jones, B.³ Goldhirsch, A.⁴ Untch, M.⁵ Smith, I.⁶ Gianni, L.⁷ Baselga, J.⁸ Bell, R.⁹ Jackisch, C.¹⁰ Cameron, D.¹¹ Dowsett, M.¹² Barrios, C.H.¹³ Steger, G.¹⁴ Huang, C.-S.¹⁵ Andersson, M.¹⁶ Inbar, M.¹⁷ Lichinitser, M.¹⁸ Lang, I.¹⁹ Nitz, U.²⁰ more..

6
- 26844536978
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
- DOI 10.1056/NEJMoa052122
- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684 (Pubitemid 41464706)
- (2005) New England Journal of Medicine , vol.353 , Issue.16 , pp. 1673-1684
- Romond, E.H.¹ Perez, E.A.² Bryant, J.³ Suman, V.J.⁴ Geyer Jr., C.E.⁵ Davidson, N.E.⁶ Tan-Chiu, E.⁷ Martino, S.⁸ Paik, S.⁹ Kaufman, P.A.¹⁰ Swain, S.M.¹¹ Pisansky, T.M.¹² Fehrenbacher, L.¹³ Kutteh, L.A.¹⁴ Vogel, V.G.¹⁵ Visscher, D.W.¹⁶ Yothers, G.¹⁷ Jenkins, R.B.¹⁸ Brown, A.M.¹⁹ Dakhil, S.R.²⁰ more..

7
- 33847063053
- The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
- DOI 10.1158/1078-0432.CCR-06-1109
- Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-2334 (Pubitemid 46698581)
- (2007) Clinical Cancer Research , vol.13 , Issue.8 , pp. 2329-2334
- Carey, L.A.¹ Dees, E.C.² Sawyer, L.³ Gatti, L.⁴ Moore, D.T.⁵ Collichio, F.⁶ Ollila, D.W.⁷ Sartor, C.I.⁸ Graham, M.L.⁹ Perou, C.M.¹⁰

8
- 23844549918
- Breast cancer molecular subtypes respond differently to preoperative chemotherapy
- DOI 10.1158/1078-0432.CCR-04-2421
- Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685 (Pubitemid 41170290)
- (2005) Clinical Cancer Research , vol.11 , Issue.16 , pp. 5678-5685
- Rouzier, R.¹ Perou, C.M.² Symmans, W.F.³ Ibrahim, N.⁴ Cristofanilli, M.⁵ Anderson, K.⁶ Hess, K.R.⁷ Stec, J.⁸ Ayers, M.⁹ Wagner, P.¹⁰ Morandi, P.¹¹ Fan, C.¹² Rabiul, I.¹³ Ross, J.S.¹⁴ Hortobagyi, G.N.¹⁵ Pusztai, L.¹⁶

9
- 37549020704
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair
- Saal LH, Gruvberger-Saal SK, Persson C, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008;40:102-107
- (2008) Nat Genet , vol.40 , pp. 102-107
- Saal, L.H.¹ Gruvberger-Saal, S.K.² Persson, C.³

10
- 49649087385
- Essential roles of PI (3)K-p110beta in cell growth, metabolism and tumorigenesis
- Jia S, Liu Z, Zhang S, et al. Essential roles of PI (3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454:776-779
- (2008) Nature , vol.454 , pp. 776-779
- Jia, S.¹ Liu, Z.² Zhang, S.³

11
- 51349148948
- PTEN-deficient cancers depend on PIK3CB
- Wee S, Wiederschain D, Maira SM, et al. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 2008;105:13057-13062
- (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 13057-13062
- Wee, S.¹ Wiederschain, D.² Maira, S.M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.